Navigation Links
Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents
Date:7/24/2013

COLUMBUS, Ohio -- Small proteins called peptides that consist of 10 to 50 amino acids are being studied as cancer vaccines and as possibly safer, more effective and less costly alternatives to the monoclonal-antibody-based drugs and small-molecule inhibitors now used to treat many malignancies.

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) have identified two regions on the HER1/EGFR receptor, a protein important for cancer-cell growth and metastasis and for poor patient survival, as targets for peptide agents.

The receptor molecule protrudes from the surface of cancer cells in abnormally high numbers. It is activated by growth factors in the blood and released by other cells in the tumor, stimulating tumor growth.

"Our findings could lead to novel peptide vaccines and mimetic inhibitors that target HER1 in tumors of the breast, lung, colon and head and neck, and that overcome many of the significant shortcomings of antibody-based drugs such as cetuximab," says principal investigator Pravin Kaumaya, PhD, director of the division of vaccine development at the OSUCCC - James.

"Such peptide agents might enable the development of combination immunotherapies using either HER2 vaccines or VEGF therapy that avoid the mechanisms of resistance or secondary treatment failures sometimes experienced with antibody treatment," says Kaumaya, who is also professor of obstetrics and gynecology, of molecular and cellular biochemistry, and of microbiology at Ohio State.

The study is published in the Journal of Immunology.

HER1 is a member of the epithelial growth factor (EGF) family of cell-surface receptors, which includes the HER2 receptor. These receptors play a central role in the development of a variety of human cancers, including certain breast cancers, lung cancer, colorectal and head and neck cancers.

Kaumaya and his colleagues evaluated three sequences of peptides to determine which were the most specific and immunogenic (i.e., raised the strongest immune response in test animals), and therefore were best suited for use as vaccines or therapeutics. The three sequences, or epitopes, were based on the site of contact between HER1 and the growth factor that normally binds with it, epithelial growth factor (EGF). Key technical findings included:

  • Two of the sequences (382-410 and 418-435) were identified as best for use as cancer therapy or a cancer vaccine;
  • The 382-410 epitope overlaps the binding site of cetuximab, an antibody agent that inhibits HER1 binding; however, the 418-435 epitope significantly inhibited tumor growth in transplantable breast and lung cancer models;
  • The vaccine constructs were highly immunogenic and established immunological memory in a rabbit model. "Overall," Kaumaya says, "our results show that the 418-435 epitope has great potential for use as a vaccine or treatment option for HER1-expressing cancers."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. University of Hawaii Cancer Center researchers report
2. Mount Sinai researchers discover mechanism behind development of autoimmune hepatitis
3. Dead gene comes to life, puts chill on inflammation, Stanford researchers find
4. Researchers identify 146 contemporary medical practices offering no net benefits
5. Protein complex linked to cancer growth may also help fight tumors, Moffitt researchers say
6. Disney researchers use encoded audio signals to provide second screen experiences at most venues
7. Researchers Discover a Gene That Is Associated with Obesity
8. Researchers report a complete description of gene expression in the human retina
9. Researchers Find That Setting Weight Loss Ranges Are More Beneficial than Specifics, Making Weight Loss Via Supplements Like Prescopodene More Likely
10. Single dose of ADHD drug can reduce fall risk in older adults -- Ben-Gurion U researchers
11. UCLA researchers find link between intestinal bacteria and white blood cell cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare ... audience, will be participating in Rare Disease Day events, hosted by the Rare ... Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid ... sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental Group ... for a dinner for two at the Cheesecake Factory. , Tickets are available ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... “Doping in Sport: How the Culture Might Change,” in conjunction with ... symposium will be held at Pepperdine University in Malibu, California. , Sir Philip ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services has ... announcement was made by Bill Monast , President ... and Nathan Feltman , executives with Home ... Services, LLC. This acquisition helps Hospice ... of technology enabled durable medical equipment (DME) solutions for ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), ... solutions for the treatment of chronic pain, today reported financial ... 31, 2016. 2016 Accomplishment & Highlights: ... year 2016, an increase of 228% as reported, over the ... 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: